Human diseases, particularly infectious diseases and cancers, pose unprecedented
challenges to public health security and the global economy. The development and …

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in
young children and elderly people. Although the virus was isolated in 1955, an effective …

Single-dose vaccines with the ability to restrict SARS-CoV-2 replication in the respiratory
tract are needed for all age groups, aiding efforts toward control of COVID-19. We developed …

There is currently no licensed vaccine for respiratory syncytial virus (RSV). Here, we assess
the effect of RSV fusion protein (F) conformation on B cell responses in a post hoc …

Respiratory syncytial virus (RSV) has eluded active vaccination efforts for more than five
decades and continues to cause substantial morbidity and mortality in infants, the …

Respiratory syncytial virus (RSV) belongs to the recently defined Pneumoviridae family,
Orthopneumovirus genus. It is the leading cause of acute bronchiolitis and one of the most …

Respiratory syncytial virus continues to pose a serious threat to the pediatric populations
worldwide. With a genomic makeup of 15,200 nucleotides, the virus encodes for 11 proteins …

Respiratory syncytial virus (RSV) is a well-known infant pathogen transmitted mainly by
droplets. It is a leading cause of upper respiratory tract infections in children, usually with a …

Despite the recent development of safe and highly effective direct-acting antivirals, hepatitis
C virus (HCV) infection remains a significant health problem. In 2016, the World Health …

The vaccine field is pursuing diverse approaches to translate the molecular insights from
analyses of effective antibodies and their targeted epitopes into immunogens capable of …